NIOX Group Past Earnings Performance
Past criteria checks 2/6
NIOX Group has been growing earnings at an average annual rate of 62.4%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 3.9% per year. NIOX Group's return on equity is 11.3%, and it has net margins of 25.8%.
Key information
62.4%
Earnings growth rate
63.6%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | -3.9% |
| Return on equity | 11.3% |
| Net Margin | 25.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
NIOX Group's (LON:NIOX) Shareholders Have More To Worry About Than Only Soft Earnings
Apr 05
We Think Shareholders Should Be Aware Of Some Factors Beyond NIOX Group's (LON:NIOX) Profit
Apr 03Recent updates
NIOX Group's (LON:NIOX) Shareholders Have More To Worry About Than Only Soft Earnings
Apr 05Are Investors Undervaluing NIOX Group Plc (LON:NIOX) By 28%?
May 17We Think Shareholders Should Be Aware Of Some Factors Beyond NIOX Group's (LON:NIOX) Profit
Apr 03We're Interested To See How Circassia Group (LON:CIR) Uses Its Cash Hoard To Grow
Jan 05Here's What Circassia Group Plc's (LON:CIR) Shareholder Ownership Structure Looks Like
Mar 13Have Insiders Been Buying Circassia Group Plc (LON:CIR) Shares This Year?
Feb 04Revenue & Expenses BreakdownBeta
How NIOX Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 37 | 10 | 20 | 2 |
| 30 Sep 23 | 36 | 9 | 19 | 2 |
| 30 Jun 23 | 35 | 8 | 18 | 3 |
| 31 Mar 23 | 33 | 11 | 18 | 3 |
| 31 Dec 22 | 31 | 14 | 17 | 3 |
| 30 Sep 22 | 30 | 14 | 17 | 4 |
| 30 Jun 22 | 29 | 13 | 17 | 4 |
| 31 Mar 22 | 28 | 8 | 18 | 4 |
| 31 Dec 21 | 28 | 2 | 19 | 5 |
| 30 Sep 21 | 28 | -9 | 21 | 5 |
| 30 Jun 21 | 27 | -19 | 23 | 6 |
| 31 Mar 21 | 26 | -23 | 25 | 6 |
| 31 Dec 20 | 24 | -27 | 27 | 6 |
| 30 Sep 20 | 26 | -23 | 29 | 6 |
| 30 Jun 20 | 27 | -18 | 32 | 7 |
| 31 Mar 20 | 31 | -18 | 35 | 7 |
| 31 Dec 19 | 35 | -17 | 37 | 7 |
| 30 Sep 19 | 37 | -24 | 44 | 8 |
| 30 Jun 19 | 39 | -32 | 52 | 8 |
| 31 Mar 19 | 43 | -39 | 59 | 10 |
| 31 Dec 18 | 48 | -47 | 66 | 11 |
| 30 Sep 18 | 52 | -50 | 66 | 11 |
| 30 Jun 18 | 56 | -53 | 67 | 12 |
| 31 Mar 18 | 51 | -57 | 64 | 13 |
| 31 Dec 17 | 46 | -60 | 60 | 13 |
| 30 Jun 17 | 30 | -53 | 47 | 17 |
| 31 Mar 17 | 27 | -45 | 44 | 17 |
| 31 Dec 16 | 23 | -37 | 42 | 17 |
| 30 Sep 16 | 22 | -46 | 42 | 31 |
| 30 Jun 16 | 21 | -42 | 43 | 36 |
| 31 Mar 16 | 16 | -46 | 35 | 42 |
| 31 Dec 15 | 11 | -50 | 27 | 47 |
| 30 Sep 15 | 6 | -45 | 18 | 44 |
| 30 Jun 15 | 1 | -40 | 10 | 41 |
| 31 Mar 15 | 0 | -38 | 8 | 40 |
| 31 Dec 14 | 0 | -35 | 7 | 39 |
| 30 Sep 14 | 0 | -32 | 6 | 33 |
| 30 Jun 14 | 0 | -29 | 6 | 28 |
| 31 Mar 14 | 0 | -24 | 5 | 25 |
Quality Earnings: NIOX has high quality earnings.
Growing Profit Margin: NIOX's current net profit margins (25.8%) are lower than last year (45%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NIOX has become profitable over the past 5 years, growing earnings by 62.4% per year.
Accelerating Growth: NIOX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: NIOX had negative earnings growth (-32.6%) over the past year, making it difficult to compare to the Biotechs industry average (-14.4%).
Return on Equity
High ROE: NIOX's Return on Equity (11.3%) is considered low.